$AUROPHARMA

Aurobindo Pharma Ltd came under pressure on Monday after the US Food and Drug Administration (USFDA) classified Eugia Pharma Specialities' Unit III manufacturing facility as "Official Action Indicated" (OAI), making the stock one of the biggest laggards in the Nifty Pharma index. Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, received the OAI classification following a USFDA inspection of its Telangana-based facility conducted between January 27 and February 6, 2026. The inspection concluded with 11 observations, and the company was informed of the regulator's decision on June 12. An OAI status signifies that the USFDA has identified significant compliance issues that could warrant regulatory or administrative action. Although the facility can continue manufacturing and supplying products that have already been approved, it will not be eligible for approvals of new drug applications until the identified concerns are adequately addressed. The regulatory development weighed on investor sentiment despite the company's assurance that the classification would not affect its ongoing operations or financial performance. Earlier this month, Aurobindo Pharma announced its foray into the biologics contract manufacturing space through the launch of TheraNym, a dedicated biologics contract manufacturing organisation (CMO). However, market focus on Monday remained firmly on the USFDA's action and its potential implications for future approvals.